← Ebola Watch

WHO's Emergency Committee Meets as Congo Passes 11,400 Confirmed Ebola Cases; Bundibugyo Vaccine Trial Set for November 26 (November 18, 2026)

November 18, 2026 · 6m 9s · Listen

Three months since WHO's Ebola emergency committee last sat down, and the case count has more than doubled. They met again yesterday. Welcome to Ebola Watch. It's Wednesday, November 18th. We start with what WHO's Director-General told that committee, and where Congo's confirmed count stands now. After that, the first vaccines designed for Bundibugyo finally have a start date.

From WHO Director-General Tedros Adhanom Ghebreyesus, opening the third meeting of the International Health Regulations Emergency Committee on Tuesday:

In that time, the number of cases has more than doubled. More than 11 000 cases and 5400 deaths have now been reported, in 67 health zones across eight provinces.

Okay, so this is the committee that decides whether it's still an international emergency. What did they decide? We don't know yet. EFE reports the committee is due to issue recommendations and say whether the outbreak still constitutes a public health emergency of international concern. We haven't seen that statement published, so for now all we have is Tedros's opening remarks. Then what did he tell them? He gave both columns. On progress, rapid transmission has been halted in most of the early epicentres, testing labs went from two to more than two dozen, there are close to 2,000 treatment beds, and about 3,000 people have recovered. But he said, in his words, progress in some places is not control of the outbreak as a whole. Four hundred to 500 new cases a week, and two-thirds of confirmed deaths still happening outside treatment centres. He also brought up travel bans, right? He did. He said some countries keep applying blanket travel restrictions, which he argues hinder the response, damage livelihoods and discourage countries from reporting quickly. He praised Kenya and Nigeria for rapid detection. He also flagged that frontline workers being paid late is causing tension and slowing the response. Which is the exact complaint MSF made on Monday. Now the number. His figures sound rounder than what we gave you yesterday. They're rounded. UAN World, citing the presidential Ebola task force, has 11,432 confirmed cases and 5,593 confirmed deaths through Sunday, November 15th, up from the 11,376 and 5,568 we cited Tuesday. That day alone added 56 confirmed cases and 25 deaths, and 18 of those deaths were in communities. The AFREEQUE newsroom, citing the ministry's November 16th situation report, goes higher still, 11,504 confirmed and 5,630 deaths. Different cut-off days, so we're giving you both. And the tracing gap? Contact follow-up was 85.1 percent nationally that day, with 5,316 contacts not seen. North Kivu was at 76.7 percent, against a 95 percent target, and its treatment centres held 118 patients for every 100 beds. On the other side, the task force says 16 health zones have gone at least 42 days without a new confirmed case. A hundred and eighteen patients per hundred beds. That's North Kivu telling you where the pressure is.

From Agence France-Presse, reporting on WHO's Geneva press conference Tuesday:

Meg Doherty, head of the WHO's science for health department, said Phase 2 clinical trials with the candidate vaccines are scheduled to begin on November 26 or 27 in Bunia, the capital of the DRC's northeastern Ituri province at the epicentre of the outbreak.

Finally, a date. On Monday all we could tell people was once national approvals come through. Right, and that's Thursday the 26th or Friday the 27th of next week. Tedros put it as early as next week at the press conference. His remarks to the committee said in the coming weeks, so treat the date as WHO's plan rather than a guarantee. The two candidates are the Oxford ChAdOx1 shot and Moderna's mRNA-1469, and both have already been through small Phase 1 trials. Phase 2 still isn't the vaccine going out to everyone, though. No. AFP explains that Phase 2 checks safety and immune response. Only if that data passes the next review can the candidates move into a full Phase 3 trial. They'll join Tumaini, the ring-vaccination trial that started on October 23rd with Ervebo, which is licensed for the Zaire species, to test whether it protects against Bundibugyo too. How big is Tumaini so far? Doherty said more than 140 people are enrolled, with thousands of contacts ultimately expected, and the trial will eventually expand beyond its single site in Bunia. Separately, Tedros told the committee more than 900 people are enrolled in treatment trials. Yesterday we promised you SAGE. Anything on Ervebo? Nothing we've seen. The vaccine advisers met Tuesday, and we haven't found any published outcome on wider Ervebo access. Tedros's own line to the committee was that vaccines are not a substitute for early care, contact tracing, isolation and safe burials. And for anyone with a trip coming up, none of this changes the rules today. The U.S. attestation for travelers who've been in Congo in the last 21 days is still in place.

If these daily briefings help you keep the numbers straight, please leave Ebola Watch a rating or a short review wherever you listen. It's how people who need this find it.

Tomorrow we'll be looking for the Emergency Committee's statement and any word from SAGE. That's Ebola Watch for today, from Lantern Podcasts. Stay well.